ArticleBMC public health2025
Longitudinal trends in mortality and its causes among migrant HIV/AIDS patients undergoing antiretroviral therapy compared to their counterparts: a cohort study, 2016-2022.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact of migrant-inclusive policy on Botswana's universal HIV treatment program: a retrospective analysis of the national HIV treatment program data (2016-2022).Frontiers in public health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionTo assess the impact of immigration status and other risk factors on mortality among HIV/AIDS patients receiving antiretroviral therapy (ART).
methodsWe conducted a cohort study (2016–2022) of 3,795 HIV/AIDS patients aged ≥ 18 years in Yunnan, China. The migrant population was defined as individuals whose household registration and current residence were located in different provinces. Mortality was analysed from patients inclusion to death or censored. Descriptive analysis results were obtained using chi-square tests, Fisher’s Exact test, t-tests, and Poisson regression models were conducted to estimate mortality outcomes([Formula: see text]).
resultsThe total follow-up time for this cohort was 14,263.0 years, with an overall mortality rate of 7.7% (294/3,795). Target population was predominantly male (68.7%) aged 25–49 years (63.3%). After adjusting for demographic and clinical characteristics, there were several variables with significances by Poisson regression, and they were migrant status, age, gender, time to ART initiation, opportunistic infections, viral load, serum creatinine level, and CD4 cell count. It revealed that migrants had a lower risk for mortality (aIRR 0.64, 95% CI: 0.40–0.97), although those 25–49 (aIRR 2.53, 95% CI:1.21–6.49) and ≥ 50 years (aIRR 7.25, 95% CI:3.48–18.55) of age exhibited a higher mortality rate, and women were at lower risk than men (aIRR 0.43, 95% CI:0.31–0.58). Delayed initiation of ART > 30 days increased the risk for mortality (aIRR 1.31,95% CI:1.04–1.67). Mortality was higher among patients with opportunistic infections (aIRR 1.58, 95% CI:1.22–2.05), as well as those with viral load ≥ 50 copies/mL (aIRR 2.77, 95% CI:2.07–3.79) and abnormal serum creatinine levels (aIRR 1.58, 95% CI:1.08–2.26). CD4 cell count ≥ 200 cells/µL were associated with lower mortality ( aIRR 0.62, 95% CI:0.46–0.82). The causes of death were dominated by respiratory diseases, cardiovascular diseases, and other non-AIDS-related diseases.
conclusionsBeing migrant was associated with a lower mortality as compared with local natives or other long-settled population. The main factors influencing the risk for mortality among HIV/AIDS patients were migrant status, age, gender, time to ART initiation, opportunistic infections, viral load, serum creatinine level, and CD4 cell count.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.